

Martina Uttenreuther-Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/281656/publications.pdf>

Version: 2024-02-01

248
papers

15,896
citations

46918

47
h-index

20307

116
g-index

254
all docs

254
docs citations

254
times ranked

13876
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01). <i>Cancer Research and Treatment</i> , 2022, 54, 109-117.	1.3	5
2	Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer. <i>Annals of Surgery</i> , 2022, 275, 467-476.	2.1	21
3	Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Cancer Research and Treatment</i> , 2022, 54, 505-516.	1.3	17
4	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 469-477.	1.3	5
5	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
6	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 565-576.	1.1	32
7	RNA Sequencing for Elucidating an Intronic Variant of Uncertain Significance (<i><i>SDHD</i></i>) Tj ETQq1 1 0.784314 <i>rgBT /Overlock 10 Tj</i>		
8	CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience. <i>Journal of Breast Cancer</i> , 2022, 25, 49.	0.8	4
9	Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01). <i>Korean Journal of Internal Medicine</i> , 2022, 37, 190-200.	0.7	2
10	Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022, 40, 279-279.	0.8	1
11	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS370-TPS370.	0.8	1
12	Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 268-268.	0.8	1
13	Abstract P5-13-36: Germline <i><i>BRCA</i></i> 1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. <i>Cancer Research</i> , 2022, 82, P5-13-36-P5-13-36.	0.4	0
14	Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC). <i>Cancer Research</i> , 2022, 82, P5-16-11-P5-16-11.	0.4	1
15	Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC). <i>Cancer Research</i> , 2022, 82, PD10-04-PD10-04.	0.4	1
16	Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis. <i>Cancer Research</i> , 2022, 82, PD8-01-PD8-01.	0.4	4
17	Abstract OT2-11-01: EMBER-3: A randomized phase 3 study of LY3484356, a novel, oral selective estrogen receptor degrader vs investigator's choice of endocrine therapy of either fulvestrant or exemestane, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. <i>Cancer Research</i> , 2022, 82, OT2-11-01-OT2-11-01.	0.4	5
18	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	13.9	474

#	ARTICLE	IF	CITATIONS
19	Three-Year Follow-Up and Response—Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3). <i>Clinical Cancer Research</i> , 2022, 28, 3277-3286.	3.2	27
20	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	1.3	1
21	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3065-3076.	0.8	97
22	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2022, 12, 7858.	1.6	3
23	Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 1190.	3.4	21
24	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	13.9	854
25	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1000-1000.	0.8	9
26	Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16107-e16107.	0.8	0
27	Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16095-e16095.	0.8	0
28	Phase 1b/2 study of GX-17 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1081-1081.	0.8	3
29	A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS611-TPS611.	0.8	1
30	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 495-505.	0.7	6
31	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. <i>Journal of Breast Cancer</i> , 2021, 24, 359.	0.8	4
32	Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2—Negative Advanced Breast Cancer. <i>Journal of Breast Cancer</i> , 2021, 24, 97.	0.8	3
33	Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 254-255.	0.8	1
34	Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance—A Matched Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 4284-4291.	0.7	16
35	Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 168-168.	0.8	5
36	Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 204-204.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	1.3	5
38	Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 77-89.	1.1	7
39	Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial. <i>Cancer Research and Treatment</i> , 2021, 53, 1084-1095.	1.3	5
40	Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 665426.	1.3	1
41	Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 583-592.	1.1	2
42	Neratinib+capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and 2 prior HER2-directed regimens. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 449-458.	1.1	2
43	Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction. <i>Data in Brief</i> , 2021, 35, 106837.	0.5	0
44	Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 573.	3.4	217
45	Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	2.3	5
46	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	0.8	2
47	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. <i>Scientific Reports</i> , 2021, 11, 10510.	1.6	3
48	Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 526-526.	0.8	32
49	RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 4012-4012.	0.8	38
50	AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4150-TPS4150.	0.8	4
51	First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 3107-3107.	0.8	2
52	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1518-1530.	0.8	153
53	Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). <i>Journal of Clinical Oncology</i> , 2021, 39, 517-517.	0.8	3
54	The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial. <i>Ecological Management and Restoration</i> , 2021, , .	0.2	2

#	ARTICLE	IF	CITATIONS
55	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. <i>Oncologist</i> , 2021, 26, e1327-e1338.	1.9	31
56	Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1309-1315.	0.5	13
57	Impact of Local Breast Cancer Recurrence on Reconstructed Breast in Nipple-Sparing Mastectomy with Immediate Reconstruction. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2021, , .	0.5	0
58	Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 1856-1864.	0.8	100
59	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5272-5279.	3.2	26
60	The Association between Herpes Zoster and Increased Cancer Risk: A Nationwide Population-Based Matched Control Study. <i>Current Oncology</i> , 2021, 28, 2720-2730.	0.9	5
61	Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 377-386.	1.1	38
62	Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12. <i>Cancer Research and Treatment</i> , 2021, 53, 671-677.	1.3	14
63	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6156-6163.	3.2	12
64	Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. <i>Lancet</i> , The, 2021, 398, 759-771.	6.3	642
65	Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting. <i>BMC Proceedings</i> , 2021, 15, 15.	1.8	5
66	Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5818-5827.	3.2	14
67	Definitive chemoradiotherapy versus esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma: A retrospective study. <i>Radiotherapy and Oncology</i> , 2021, 162, 112-118.	0.3	7
68	Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. <i>Cancer Medicine</i> , 2021, 10, 1745-1758.	1.3	1
69	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	3.4	66
70	338 – Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study. , 2021, 9, A364-A364.		1
71	Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110619.	1.4	4
72	Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy. <i>Cancer Research and Treatment</i> , 2021, , .	1.3	7

#	ARTICLE	IF	CITATIONS
73	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6267.	1.7	7
74	Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade. <i>Clinical Breast Cancer</i> , 2020, 20, 25-32.	1.1	7
75	Clinical effectiveness and safety of self-expanding metal stent placement following palliative chemotherapy in patients with advanced esophageal cancer. <i>Abdominal Radiology</i> , 2020, 45, 563-570.	1.0	7
76	Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 315-324.	1.1	5
77	Prognostic value of neutrophil-to-lymphocyte ratio in older patients with head and neck cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 417-422.	0.5	14
78	Characteristics of metastatic brachial plexopathy in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 1913-1918.	1.0	17
79	Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e53-e62.	0.7	2
80	Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2020, 27, 1627-1635.	0.7	22
81	Is asymptomatic surveillance beneficial after standard treatment? A 10-year survival analysis of recurrent BC patients by detection method of recurrence. <i>Breast Journal</i> , 2020, 26, 556-559.	0.4	1
82	A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. <i>Investigational New Drugs</i> , 2020, 38, 866-873.	1.2	2
83	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	13.9	1,143
84	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	0.8	614
85	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2020, 21, 1283-1295.	5.1	213
86	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 17466.	1.6	11
87	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	0.5	1
88	Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2020, 155, 1142.	2.2	41
89	Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 3359-3369.	1.2	12
90	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With 2 HER2-Directed Regimens: Phase III NALA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3138-3149.	0.8	355

#	ARTICLE	IF	CITATIONS
91	Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. , 2020, 8, e000342.		32
92	Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitorsâ€”proceedings from breast cancer expert group meeting. Chinese Clinical Oncology, 2020, 9, 61-61.	0.4	4
93	Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13â€“01). BMC Cancer, 2020, 20, 813.	1.1	39
94	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. JCO Precision Oncology, 2020, 4, 1012-1024.	1.5	11
95	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 519-530.	5.1	441
96	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 763-775.	5.1	144
97	Oncologic Outcomes of Nipple-sparing Mastectomy and Immediate Reconstruction After Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 2020, Publish Ahead of Print, e1196-e1201.	2.1	9
98	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. Journal of Clinical Oncology, 2020, 38, 1023-1023.	0.8	29
99	Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.. Journal of Clinical Oncology, 2020, 38, 1036-1036.	0.8	12
100	SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).. Journal of Clinical Oncology, 2020, 38, 1040-1040.	0.8	2
101	Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.. Journal of Clinical Oncology, 2020, 38, 6503-6503.	0.8	15
102	A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent or metastatic adenoid cystic carcinoma.. Journal of Clinical Oncology, 2020, 38, TPS6597-TPS6597.	0.8	1
103	Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen. Journal of Breast Cancer, 2020, 23, 553.	0.8	2
104	Preliminary safety and efficacy of GX-17, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).. Journal of Clinical Oncology, 2020, 38, 1072-1072.	0.8	3
105	Prognostic significance of lymph node ratio after neoadjuvant chemoradiation therapy for esophageal squamous cell carcinoma. Radiation Oncology Journal, 2020, 38, 244-252.	0.7	1
106	261â€“..Association of T-cellâ€“inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180. , 2020, , .		1
107	A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	10
108	MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy. Scientific Reports, 2019, 9, 11991.	1.6	17

#	ARTICLE	IF	CITATIONS
109	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. <i>Journal of Breast Cancer</i> , 2019, 22, 387.	0.8	3
110	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1506-1517.	5.1	767
111	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1750-1759.	5.1	86
112	Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). <i>British Journal of Cancer</i> , 2019, 121, 985-990.	2.9	9
113	Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer. <i>JAMA Surgery</i> , 2019, 154, 1030.	2.2	75
114	Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia. <i>Future Oncology</i> , 2019, 15, 3243-3253.	1.1	2
115	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	1.1	8
116	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. <i>Targeted Oncology</i> , 2019, 14, 591-601.	1.7	43
117	A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). <i>Anticancer Research</i> , 2019, 39, 5123-5133.	0.5	23
118	Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. <i>Journal of Global Oncology</i> , 2019, 5, 1-19.	0.5	34
119	Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2019, 39, 3111-3119.	0.5	12
120	Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. <i>European Journal of Cancer</i> , 2019, 116, 98-106.	1.3	54
121	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq1 1 0.784314 5 BT /Ov	3.7	14
122	HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 237-250.	1.1	84
123	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
124	Diagnostic accuracy and safety of ^{18}F -fluoro- $^{17}\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 546-555.	5.1	85
125	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 2166-2174.	0.7	12
126	Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus. <i>JAMA Oncology</i> , 2019, 5, 546.	3.4	366

#	ARTICLE	IF	CITATIONS
127	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 393, 156-167.	6.3	1,153
128	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1002-1002.	0.8	71
129	A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10.) <i>Tj ETQq1 1 0.7843 14 rgBI4/Overlo</i>	0.8	14
130	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1013-1013.	0.8	26
131	End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1020-1020.	0.8	22
132	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4010-4010.	0.8	38
133	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4032-4032.	0.8	4
134	Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6081-6081.	0.8	6
135	Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS1113-TPS1113.	0.8	11
136	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2-2.	0.8	136
137	Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). <i>Cancer Research and Treatment</i> , 2019, 51, 43-52.	1.3	34
138	BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1527-1539.	1.3	5
139	Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6024-6024.	0.8	1
140	Prognostic stratification of locoregional esophageal cancer (EC) patients (pts) treated with definitive chemoradiotherapy (dCRT).. <i>Journal of Clinical Oncology</i> , 2019, 37, e15578-e15578.	0.8	0
141	Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2018, 92, 69-76.	1.3	11
142	Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. <i>British Journal of Cancer</i> , 2018, 118, 344-352.	2.9	7
143	Radiation-induced esophageal strictures treated with fluoroscopic balloon dilation: clinical outcomes and factors influencing recurrence in 62 patients. <i>Acta Radiologica</i> , 2018, 59, 313-321.	0.5	18
144	Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up. <i>International Journal of Clinical Oncology</i> , 2018, 23, 52-58.	1.0	13

#	ARTICLE	IF	CITATIONS
145	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	1.3	10
146	<i>FcrR3A</i>-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment. <i>Journal of Breast Cancer</i> , 2018, 21, 45.	0.8	0
147	How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. <i>ESMO Open</i> , 2018, 3, e000357.	2.0	112
148	Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. <i>Npj Breast Cancer</i> , 2018, 4, 19.	2.3	19
149	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	2.3	46
150	Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study. <i>Journal of Breast Cancer</i> , 2018, 21, 70.	0.8	12
151	Risk factors for competing non-cancer mortality after definitive treatment for advanced-stage head and neck cancer. <i>Oral Diseases</i> , 2018, 24, 1217-1225.	1.5	5
152	Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1008-1008.	0.8	24
153	IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for <i>PIK3CA/AKT1/PTEN</i>-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1117-TPS1117.	0.8	16
154	Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study. <i>Oncotarget</i> , 2018, 9, 3875-3886.	0.8	9
155	No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery. <i>Cancer Research and Treatment</i> , 2018, 50, 275-282.	1.3	13
156	A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS3111-TPS3111.	0.8	0
157	Quality of life (QoL) outcomes including neuropathy associated scale (FACT-I) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC): Korean Cancer Study Group trial (KCSG BR13-11).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10117-10117.	0.8	0
158	Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series. <i>Clinical Endoscopy</i> , 2018, 51, 470-477.	0.6	3
159	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 323-335.	5.1	173
160	Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 743-754.	5.1	372
161	Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. <i>New England Journal of Medicine</i> , 2017, 376, 2147-2159.	13.9	1,228
162	Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2017, 127, E437-E442.	1.1	73

#	ARTICLE	IF	CITATIONS
163	Quality of life on TSUâ€68: Combination of docetaxel and TSUâ€68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 365-371.	0.7	0
164	Ibulicycline sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 83, 47-55.	1.2	13
165	Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced-stage head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 716-723.	0.9	37
166	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1360-1372.	5.1	377
167	Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. <i>Lancet Oncology</i> , The, 2017, 18, e638.	5.1	7
168	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
169	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.	1.3	23
170	Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. <i>Thyroid</i> , 2017, 27, 1135-1141.	2.4	37
171	A Randomized Feasibility Study of ¹⁸ F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptorâ€Rich Postmenopausal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 563-568.	2.8	40
172	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. <i>Journal of Clinical Oncology</i> , 2017, 35, 556-556.	0.8	60
173	Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 443-451.	0.7	4
174	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. <i>Cancer Research and Treatment</i> , 2017, 49, 423-429.	1.3	7
175	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. <i>PLoS Medicine</i> , 2016, 13, e1002136.	3.9	28
176	Expression of <i>FOXM1</i> and related proteins in breast cancer molecular subtypes. <i>International Journal of Experimental Pathology</i> , 2016, 97, 170-177.	0.6	43
177	Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 42.	1.1	25
178	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1557.	3.4	242
179	An Introduction to a Head and Neck Cancer-Specific Frailty Index and Its Clinical Implications in Elderly Patients: A Prospective Observational Study Focusing on Respiratory and Swallowing Functions. <i>Oncologist</i> , 2016, 21, 1091-1098.	1.9	31
180	Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 685-695.	1.1	20

#	ARTICLE	IF	CITATIONS
181	Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer. <i>Cancer</i> , 2016, 122, 131-140.	2.0	53
182	Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 2336-2342.	2.3	69
183	Docetaxel-based adjuvant therapy for breast cancer patients in Asia-Pacific region: Results from 5 years follow-up on Asia-Pacific Breast Initiative-I. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 125-132.	0.7	5
184	HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant+adjuvant trastuzumab after 2 years of treatment-free follow-up. <i>European Journal of Cancer</i> , 2016, 62, 62-75.	1.3	64
185	Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. <i>Breast</i> , 2016, 28, 67-72.	0.9	33
186	Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 357-366.	5.1	125
187	Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1031-1040.	1.2	38
188	Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 295-304.	1.2	10
189	Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 330-334.	0.3	84
190	Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). <i>Radiotherapy and Oncology</i> , 2016, 118, 244-250.	0.3	43
191	Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer. <i>Quality of Life Research</i> , 2016, 25, 165-174.	1.5	19
192	Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1003-1003.	0.8	21
193	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1074-1074.	0.8	2
194	BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6008-6008.	0.8	9
195	COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS1100-TPS1100.	0.8	2
196	Synchronous second primary cancers in patients with squamous esophageal cancer: clinical features and survival outcome. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 253-259.	0.7	24
197	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1373-1381.	1.3	9
198	Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 499-507.	1.3	0

#	ARTICLE	IF	CITATIONS
199	Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. <i>Cancer</i> , 2015, 121, 2612-2617.	2.0	63
200	A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15031.	1.8	6
201	Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers. <i>PLoS ONE</i> , 2015, 10, e0137885.	1.1	20
202	Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II. <i>Journal of Breast Cancer</i> , 2015, 18, 356.	0.8	7
203	Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 489-496.	0.4	39
204	Raloxifene Induces Autophagy-Dependent Cell Death in Breast Cancer Cells via the Activation of AMP-Activated Protein Kinase. <i>Molecules and Cells</i> , 2015, 38, 138-144.	1.0	51
205	Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. <i>Cellular and Molecular Immunology</i> , 2015, 12, 87-95.	4.8	57
206	Effect of Metformin on Progression of Head and Neck Cancers, Occurrence of Second Primary Cancers, and Cause-Specific Survival. <i>Oncologist</i> , 2015, 20, 546-553.	1.9	20
207	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	1.1	17
208	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1700-1710.	5.1	108
209	A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1014-1014.	0.8	8
210	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-610.	0.8	3
211	Safety of eribulin in Korean patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e12031-e12031.	0.8	3
212	LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS1111-TPS1111.	0.8	3
213	A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 406-415.	1.3	6
214	Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11579-e11579.	0.8	2
215	Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 995-1003.	1.1	8
216	Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling. <i>Breast Cancer Research</i> , 2014, 16, 479.	2.2	58

#	ARTICLE	IF	CITATIONS
217	Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 689-699.	5.1	595
218	Prognostic factors in patients with head and neck squamous cell carcinoma with cN3 neck disease: a retrospective case-control study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 178-185.	0.2	4
219	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
220	Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: High rate of systemic failure warrants targeted therapy. <i>Oral Oncology</i> , 2014, 50, e64-e66.	0.8	44
221	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. <i>Lancet Oncology, The</i> , 2014, 15, 1137-1146.	5.1	382
222	Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. <i>Investigational New Drugs</i> , 2014, 32, 753-761.	1.2	5
223	Relationship between tumor biomarkers (BM) and efficacy in TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice (TPC) in HER2-positive advanced breast cancer (BC) previously treated with trastuzumab and lapatinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, 605-605.	0.8	2
224	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with ^{>131} I-refractory differentiated thyroid cancer (SELECT).. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA6008-LBA6008.	0.8	23
225	Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice (TPC) in patients with pretreated HER2-positive advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 153-153.	0.8	3
226	Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS665-TPS665.	0.8	1
227	Comparison of concurrent chemoradiation therapy with 3-weekly versus weekly cisplatin in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II noninferiority trial (KCSG-HN10-02).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6023-6023.	0.8	0
228	Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 565-575.	1.1	32
229	Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 201-207.	1.1	23
230	Clinical Characteristics and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck. <i>Laryngoscope</i> , 2013, 123, 1430-1438.	1.1	38
231	p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry. <i>Acta Oto-Laryngologica</i> , 2013, 133, 297-304.	0.3	20
232	Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 336-341.	0.8	21
233	Effect Modification of Hormonal Therapy by p53 Status in Invasive Breast Cancer. <i>Journal of Breast Cancer</i> , 2013, 16, 386.	0.8	8
234	Stage, biology, and age.. <i>Journal of Clinical Oncology</i> , 2013, 31, e11512-e11512.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Claudin 1, 3, 4, and 7 expression in triple-negative breast cancer.. Journal of Clinical Oncology, 2013, 31, 1070-1070.	0.8	16
236	Importance of FOXP3 in prognosis and its relationship with p16 in tonsillar squamous cell carcinoma. Anticancer Research, 2013, 33, 5667-73.	0.5	15
237	Translation and validation of Korean Functional Assessment of Cancer Therapy-Esophageal (FACT-E) scale with squamous cell carcinoma and chemoradiation-only patients. Quality of Life Research, 2012, 21, 1451-1457.	1.5	3
238	A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 2012, 133, 1057-1065.	1.1	183
239	The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer. Nuclear Medicine and Molecular Imaging, 2012, 46, 57-64.	0.6	13
240	Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemotherapy and Pharmacology, 2012, 69, 655-663.	1.1	17
241	Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2012, 30, e11508-e11508.	0.8	0
242	Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. Breast Cancer Research and Treatment, 2011, 128, 171-177.	1.1	22
243	S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?. Expert Review of Anticancer Therapy, 2010, 10, 659-662.	1.1	5
244	Metastatic Tumors to the Breast from Extramammary Malignancies. Korean Journal of Pathology, 2010, 44, 70.	1.2	1
245	Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study. Current Therapeutic Research, 2007, 68, 193-204.	0.5	1
246	In vitro Priming of Myeloma Antigen-specific Allogeneic Donor T Cells with Idiotype Pulsed Dendritic Cells. Leukemia and Lymphoma, 2003, 44, 1201-1208.	0.6	14
247	Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head and Neck, 2001, 23, 223-229.	0.9	10
248	Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories. Journal of Breast Cancer, 0, 25, .	0.8	2